Ernest C. Borden obtained his medical degree from Duke University and jointed Cleveland clinic in 1998 to direct the Center for Cancer Drug Discovery and Development. In 2005, the five laboratories in the Case Western Reserve Cleveland Clinic College of Medicine were integrated to form the Center for Hematology and Oncology Molecular Therapeutics (CHOMT) with Dr. Borden named as Director. He is also a staff member in the Department of Solid Tumor Oncology and a Professor in Cancer Biology in Lerner Research Institute.
In the 1980s, he was amongst the first to initiate clinical trials of interferons, the first human protein effective in stimulating immune mechanisms to fight cancer. In addition to developing improved approaches to clinical assessment of interferons and its inducers, Dr. Borden's laboratory has focused on function and action of genes stimulated by interferons and anti-tumor effects of other biological therapeutics such as monoclonal antibodies. In addition to targeted biological therapies, he has an international reputation for research and treatment of melanomas and sarcomas. Dr. Borden has been listed in "Best Doctors" in America for the past 10 years.
(Biography as of November 2007)
